Roth Capital reiterated coverage on CalAmp with a new price target
$CAMP
Roth Capital reiterated coverage of CalAmp with a rating of Buy and set a new price target of $18.50 from $19.00 previously
Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/27/2025 | $8.00 | Outperform | Wedbush |
| 11/5/2024 | Outperform | William Blair | |
| 11/5/2024 | $18.00 | Overweight | Piper Sandler |
| 11/5/2024 | $23.00 | Overweight | JP Morgan |
| 8/16/2022 | $8.00 → $10.00 | Hold → Buy | Craig Hallum |
| 12/22/2021 | $15.00 → $14.00 | Buy | Canaccord Genuity |
| 12/22/2021 | $14.00 → $10.00 | Buy → Hold | Craig-Hallum |
| 9/24/2021 | $16.00 → $14.00 | Buy | Craig Hallum |
4/A - Camp4 Therapeutics Corp (0001736730) (Issuer)
4 - Camp4 Therapeutics Corp (0001736730) (Issuer)
4 - Camp4 Therapeutics Corp (0001736730) (Issuer)
Wedbush initiated coverage of CAMP4 Therapeutics with a rating of Outperform and set a new price target of $8.00
William Blair initiated coverage of CAMP4 Therapeutics with a rating of Outperform
Piper Sandler initiated coverage of CAMP4 Therapeutics with a rating of Overweight and set a new price target of $18.00
4 - Camp4 Therapeutics Corp (0001736730) (Issuer)
4 - Camp4 Therapeutics Corp (0001736730) (Issuer)
4 - Camp4 Therapeutics Corp (0001736730) (Issuer)
Paris, France--(Newsfile Corp. - June 30, 2025) - Sequans Communications S.A. (NYSE:SQNS), a leading innovator in cellular IoT semiconductor solutions, today announced the appointment of Jason W. Cohenour to its Board of Directors.Mr. Cohenour brings more than 30 years of executive leadership experience across sales, operations, and international mergers and acquisitions. He served as President, CEO, and Director of Sierra Wireless, Inc. (TSX:SW) (NASDAQ:SWIR) from 2005 to 2018, where he led a strategic transformation that created a global leader in the Internet of Things and drove company revenues to nearly USD $800 million. Prior to his CEO role, he held several senior positions at Sierra
Haploinsufficient SYNGAP1 mice treated with CMP-SYNGAP-01 demonstrated an increase in SYNGAP1 protein levels; treatment rescued multiple SYNGAP1-dependent behavioral phenotypes CMP-SYNGAP-01 administration led to a significant increase in SYNGAP1 protein levels in relevant brain regions in non-human primates (NHPs) Patient safety and pharmacokinetic data from single ascending dose (SAD) cohorts of the first-in-human Phase 1 clinical trial of CMP-CPS-001 in healthy volunteers highlighted CAMBRIDGE, Mass., May 16, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4") (NASDAQ:CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting th
Phase 1 clinical trial of CMP-CPS-001 in Urea Cycle Disorders (UCDs) ongoing, with dosing completed in multiple ascending dose (MAD) cohort 3; safety, pharmacokinetic, and pharmacodynamic data expected Q4 2025CTA successfully submitted in Europe for Phase 1b clinical trial in female OTC heterozygotesNominated development candidate, CMP-SYNGAP-01, to address SYNGAP1-related disorders; GLP toxicology studies expected to be initiated in 2025American Society of Cell and Gene Therapy (ASGCT) oral presentations to highlight meaningful increase in SYNGAP1 protein, driven by lead ASO candidate, CMP-SYNGAP-01, in non-human primates (NHP) and review interim SAD data from the Phase 1 trial of CMP-CPS-0
8-K - Camp4 Therapeutics Corp (0001736730) (Filer)
8-K - Camp4 Therapeutics Corp (0001736730) (Filer)
SCHEDULE 13G - Camp4 Therapeutics Corp (0001736730) (Subject)
IRVINE, Calif., Jan. 09, 2024 (GLOBE NEWSWIRE) -- CalAmp (NASDAQ:CAMP), a connected intelligence company that helps organizations monitor, track and protect their vital assets, today reported financial results for its third quarter of fiscal year 2024 ended November 30, 2023. Third Quarter Fiscal Year 2024 Financial Overview Revenue was $53.6 million, representing a 13% decline QoQ and a 32% decline YoY driven primarily by softer demand in the TSP market segment.Gross margin was 33%, representing a decline of approximately 340 bps QoQ and 100 bps decline YoY as a result of a shift in product mix and a higher-than-normal reserve for excess and obsolete inventory.S&SS revenue was $34.5
IRVINE, Calif., Dec. 26, 2023 (GLOBE NEWSWIRE) -- CalAmp (NASDAQ:CAMP), a leading telematics solution provider that helps organizations improve operational performance, today announced that it will release its fiscal 2024 third quarter financial results after market close on Tuesday, January 9, 2024. In addition, the Company will host a conference call at 5:00 p.m. Eastern (2:00 p.m. Pacific) on January 9, 2024, to discuss its financial results. The call may be accessed via webcast by visiting the Investor Relations section of CalAmp's website at CalAmp IR Web Site. Please go to the website at least 15 minutes early to register, download and install any necessary audio software. A repla
IRVINE, Calif., Dec. 18, 2023 (GLOBE NEWSWIRE) -- CalAmp (NASDAQ:CAMP), a connected intelligence company helping people and organizations improve operational performance with telematics solutions, today announced the closing of a $45 million strategic financing with Lynrock Lake Master Fund LP ("Lynrock") in the form of a term loan maturing in November 2027. Lynrock is an existing holder of a large majority of CalAmp's 2.00% Convertible Senior Notes maturing in August 2025 (the "Notes"). In connection with the execution of the term loan agreement, CalAmp is amending the Notes to add a security interest. "As a long-standing investor in CalAmp, we are pleased to provide the company with add
SC 13G - Camp4 Therapeutics Corp (0001736730) (Subject)
SC 13D - Camp4 Therapeutics Corp (0001736730) (Subject)
SC 13G - Camp4 Therapeutics Corp (0001736730) (Subject)
Paris, France--(Newsfile Corp. - June 30, 2025) - Sequans Communications S.A. (NYSE:SQNS), a leading innovator in cellular IoT semiconductor solutions, today announced the appointment of Jason W. Cohenour to its Board of Directors.Mr. Cohenour brings more than 30 years of executive leadership experience across sales, operations, and international mergers and acquisitions. He served as President, CEO, and Director of Sierra Wireless, Inc. (TSX:SW) (NASDAQ:SWIR) from 2005 to 2018, where he led a strategic transformation that created a global leader in the Internet of Things and drove company revenues to nearly USD $800 million. Prior to his CEO role, he held several senior positions at Sierra
With decades of experience in pharmaceutical development and extensive genetic medicine expertise, Doug E. Williams, Ph.D., and Murray Stewart, DM FRCP, will provide strategic guidance for CAMP4's multiple drug development efforts CAMBRIDGE, Mass., March 18, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4") (NASDAQ:CAMP), a clinical-stage biotechnology company developing a pipeline of regRNA-targeting antisense oligonucleotide (ASO) therapies to upregulate gene expression to restore healthy protein levels, today announced the appointments of Doug E. Williams, Ph.D., and Murray Stewart, DM FRCP, to the Company's Board of Directors. "We are delighted to welcome Drs. William
CAMBRIDGE, Mass., Dec. 10, 2024 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4") (NASDAQ:CAMP), a clinical-stage biotechnology company developing a pipeline of regRNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels across a range of genetic diseases, today announced the appointments of John Maraganore, Ph.D., and Rachel Meyers, Ph.D., as strategic advisors to the Company. For nearly 20 years, Dr. Maraganore served as the founding Chief Executive Officer and Director of Alnylam where he led the company's programs in RNA interference through global commercialization, resulting in the launch of the first four RNAi th